Therapeutic effects of micheliolide on a murine model of rheumatoid arthritis

Xu,Hua; Wang,Jian; Wang,Chijuan; Chang,Guoqiang; Lin,Yani; Zhang,Hongju; Zhang,Hairui; Li,Qinghua; Pang,Tianxiang

doi:10.3892/mmr.2014.2767

Therapeutic effects of micheliolide on a murine model of rheumatoid arthritis

Authors:
- Hua Xu
- Jian Wang
- Chijuan Wang
- Guoqiang Chang
- Yani Lin
- Hongju Zhang
- Hairui Zhang
- Qinghua Li
- Tianxiang Pang
View Affiliations

Affiliations: State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, P.R. China
Published online on: October 24, 2014 https://doi.org/10.3892/mmr.2014.2767
Pages: 489-493

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Rheumatoid arthritis (RA) is a systemic autoimmune disease and collagen‑induced arthritis (CIA) is an animal model for RA. Micheliolide (MCL) is a novel compound with strong anti‑inflammatory effects. The present study was conducted to evaluate the therapeutic effects of MCL on RA. Mice were randomly divided into four groups and the CIA model mice were treated with methotrexate (MTX), MCL and dimethyl sulfoxide. A score associated with the severity of arthritis was assigned on alternate days from the 22nd day for 60 days. Histopathological changes and the serum levels of cytokines were measured on day 85. The results demonstrated that the MCL treatment group had arthritis scores lower than the CIA group and higher than the MTX group; compared with the CIA group, MCL and MTX significantly reduced the swelling of the paws and suppressed the degeneration of articular cartilage. Expression levels of macrophage colony‑stimulating factor (M‑CSF), tissue inhibitors of metalloproteinases‑1 (TIMP‑1) and complement component 5a (C5/C5a) were lower in the mice with arthritis compared with normal mice, however, following treatment with MCL and MTX, all the mice exhibited significant recovery to differing degrees. Unlike the MTX group, the MCL group failed to recover the level of soluble intercellular adhesion molecule‑1. In addition, the cytokine of B‑lymphocyte chemoattractant (BLC) solely presented in the MCL group. These results suggest that MCL may be considered for use as a novel therapeutic treatment against RA and that changes in the expression of cytokines C5/C5a, TIMP‑1, M‑CSF and BLC may underlie the mechanism by which MCL effects changes in this disease.

View Figures

View References

1	Zhang Y, Xu W, Li H, et al: Therapeutic effects of total alkaloids of Tripterygium wilfordii Hook f. on collagen-induced arthritis in rats. J Ethnopharmacol. 145:699–705. 2013. View Article : Google Scholar : PubMed/NCBI
2	Vingsbo-Lundberg C, Nordquist N, Olofsson P, et al: Genetic control of arthritis onset, severity and chronicity in a model for rheumatoid arthritis in rats. Nat Genet. 20:401–404. 1998. View Article : Google Scholar : PubMed/NCBI
3	Choy EH and Panayi GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 344:907–916. 2001. View Article : Google Scholar : PubMed/NCBI
4	Lee Dm and Weinblatt MB: Rheumatoid arthritis. Lancet. 15:903–911. 2001.
5	Schall A and Reiser O: Synthesis of biologically active guaianolides with a trans-annulated lactone moiety. Eur J Org Chem. 2008:2353–2364. 2008. View Article : Google Scholar
6	Ma WW, Shi QQ, Ding YH, et al: Synthesis of micheliolide derivatives and their activities against AML progenitor cells. Molecules. 18:5980–5992. 2013. View Article : Google Scholar : PubMed/NCBI
7	Zhai JD, Li D, Long J, et al: Biomimetic semisynthesis of arglabin from parthenolide. J Org Chem. 77:7103–7107. 2012. View Article : Google Scholar : PubMed/NCBI
8	Ghantous A, Sinjab A, Herceg Z and Darwiche N: Parthenolide: from plant shoots to cancer roots. Drug Discov Today. 18:894–905. 2013. View Article : Google Scholar : PubMed/NCBI
9	Zhang Q, Lu Y, Ding Y, et al: Guaianolide sesquiterpene lactones, a source to discover agents that selectively inhibit acute myelogenous leukemia stem and progenitor cells. J Med Chem. 55:8757–8769. 2012.
10	Sokka T and Pincus T: Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice:methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. J Rheumatol. 29:2521–2524. 2002.PubMed/NCBI
11	Swierkot J and Szechiński J: Methotrexate in rheumatoid arthritis. Pharmacol Rep. 58:473–492. 2006.
12	Cronstein BN: Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 57:163–172. 2005. View Article : Google Scholar : PubMed/NCBI
13	Pincus T, Yazici Y, Sokka T, et al: Methotrexate as the “anchor drug” for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol. 21:S179–S185. 2003.
14	Van der, Heijden JW, Dijkmans BA, et al: Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs--from bench to bedside. Nat Clin Pract Rheumatol. 3:26–34. 2007.PubMed/NCBI
15	Brand DD, Latham KA and Rosloniec EF: Collagen-induced arthritis. Nat Protoc. 2:1269–1275. 2007. View Article : Google Scholar
16	Suszko A and Obminska-Mrukowicz B: Influence of polysaccharide fractions isolated from Caitha palustris L. on the cellular immune response in collagen-induced arthritis (CIA) in mice. A comparison with methotrexate. J Ethnopharmacol. 145:109–117. 2013. View Article : Google Scholar : PubMed/NCBI
17	Cuzzocrea S, Ayroldi E, Di Paola R, et al: Role of glucocorticoid-induced TNF receptor family gene (GITR) in collagen-induced arthritis. FASEB J. 19:1253–1265. 2005. View Article : Google Scholar : PubMed/NCBI
18	Xinqiang S, Fei L, Nan L, Yuan L, et al: Therapeutic efficacy of experimental rheumatoid arthritis with low-dose methotrexate by increasing partially CD4+CD25+Treg cells and inducing Th1 to Th2 shift in both cells and cytokines. Biomed Pharmacother. 64:463–471. 2010. View Article : Google Scholar
19	Firestein GS: Evolving concepts of rheumatoid arthritis. Nature. 423:356–361. 2003. View Article : Google Scholar : PubMed/NCBI
20	Wildbaum G, Nahir MA and Karin N: Beneficial autoimmunity to proinflammatory mediators restrains the consequences of self-destructive immunity. Immunity. 19:679–688. 2003. View Article : Google Scholar : PubMed/NCBI
21	Sinha AA, Lopez MT and McDevitt HO: Autoimmune diseases: the failure of self tolerance. Science. 248:1380–1388. 1990. View Article : Google Scholar : PubMed/NCBI
22	Zhou J, Xiao C, Zhao L, et al: The effect of triptolide on CD4+ and CD8+ cells in Peyer’s patch of SD rats with collagen induced arthritis. Int Immunopharmacol. 6:198–203. 2006.
23	Ma N, Xing C, Xiao H, et al: C5a regulates IL-12 (+) DC migration to induce pathogenic Th1 and Th17 cells in sepsis. PLoS One. 8:e697792013. View Article : Google Scholar : PubMed/NCBI
24	Laudes IJ, Chu JC, Huber-Lang M, et al: Expression and function of C5a receptor in mouse microvascular endothelial cells. J Immunol. 169:5962–5970. 2002. View Article : Google Scholar : PubMed/NCBI
25	Ries C: Cytokine functions of TIMP-1. Cell Mol Life Sci. 71:659–672. 2014. View Article : Google Scholar : PubMed/NCBI
26	Djafarzadeh R, Mojaat A, Vicente AB, et al: Exogenously added GPI-anchored tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) displays enhanced and novel biological activities. Biol Chem. 385:655–663. 2004. View Article : Google Scholar
27	Souza PP and Lerner UH: The role of cytokines in inflammatory bone loss. Immunol Invest. 42:555–622. 2013. View Article : Google Scholar : PubMed/NCBI
28	Fei X, Hongxiang Z, Qi C and Daozhen C: Maternal plasma levels of endothelial dysfunction mediators including AM, CGRP, sICAM-1 and tHcy in pre-eclampsia. Adv Clin Exp Med. 21:573–579. 2012.PubMed/NCBI